A retrospective study showed that the ORR and DCR at 6 months of advanced NSCLC patients with EGFR ex20ins treated with first-line platinum based chemotherapy were 19.2% and 41.3% (10). This evidence concerns the gene EGFR and non-small cell lung carcinoma.